Elevance Health/$ELV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Elevance Health
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
- Ticker
- $ELV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 96,615
- Headquarters
- Indianapolis, United States
- Website
- www.elevancehealth.com
Elevance Health Metrics
BasicAdvanced
$95B
18.77
$23.44
0.71
$6.87
1.56%
Price and volume
Market cap
$95B
Beta
0.71
52-week high
$450.69
52-week low
$274.84
Average daily volume
1.3M
Dividend rate
$6.87
Financial strength
Current ratio
1.469
Quick ratio
1.335
Long term debt to equity
0.678
Total debt to equity
0.687
Dividend payout ratio (TTM)
29.17%
Interest coverage (TTM)
5.55%
Profitability
EBITDA (TTM)
8,713
Gross margin (TTM)
26.43%
Net profit margin (TTM)
2.55%
Operating margin (TTM)
3.98%
Effective tax rate (TTM)
18.35%
Revenue per employee (TTM)
$2,090,000
Management effectiveness
Return on assets (TTM)
4.00%
Return on equity (TTM)
11.48%
Valuation
Price to earnings (TTM)
18.773
Price to revenue (TTM)
0.477
Price to book
2.13
Price to tangible book (TTM)
17.41
Price to free cash flow (TTM)
14.764
Free cash flow yield (TTM)
6.77%
Free cash flow per share (TTM)
29.799
Dividend yield (TTM)
1.56%
Forward dividend yield
1.56%
Growth
Revenue change (TTM)
3.60%
Earnings per share change (TTM)
-3.90%
3-year revenue growth (CAGR)
6.17%
10-year revenue growth (CAGR)
9.24%
3-year earnings per share growth (CAGR)
-2.28%
10-year earnings per share growth (CAGR)
10.65%
3-year dividend per share growth (CAGR)
6.30%
10-year dividend per share growth (CAGR)
10.31%
What the Analysts think about Elevance Health
Analyst ratings (Buy, Hold, Sell) for Elevance Health stock.
Analyst projections of the future price of Elevance Health stock.
Bulls say / Bears say
Elevance beat expectations in Q2 and raised its 2026 adjusted EPS guidance to at least $27. Management also expects at least 12% adjusted EPS growth in 2027, pointing to a stronger earnings trajectory. (Financial Times)
Carelon revenue grew 7.9% in Q1, with growth from risk-based services and CarelonRx. That gives Elevance a growing source of revenue beyond its core health insurance business. (Elevance Health)
The final 2027 Medicare Advantage payment increase was 2.48%, well above the earlier 0.09% proposal. Higher federal funding could improve the economics of Elevance’s Medicare Advantage business. (Reuters)
Medical costs remain a margin risk: Elevance’s Q2 benefit expense ratio rose 80 basis points year on year, with elevated cost trends in government plans among the causes. (Financial Times)
Membership is declining in Medicare Advantage, Medicaid and employer risk plans. Those losses offset higher premium yields and CarelonRx growth, limiting Q2 revenue growth to 0.8%. (Financial Times)
Elevance recorded a $935 million accrual for a CMS sanction, creating a substantial regulatory cost and potential cash burden even as adjusted earnings guidance rose. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
Elevance Health Financial Performance
Revenues and expenses
Elevance Health Earnings Performance
Company profitability
Upcoming events
Elevance Health News
AllArticlesVideos
Funds containing Elevance Health
AllUSDEURGBP
Fund name | Fund size | $ELV weighting |
|---|---|---|
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 1.53% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 1.53% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 1.47% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 1.40% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 1.40% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.